April 2014


Hello Isomark Friends and Partners, 
Isomark is off to a good start in 2014. We continue to receive strong interest from the healthcare community focused on how Isomark can improve patient care and reduce costs. 


While the costs and deaths associated with late-diagnosed and untreated infections are known to many in involved in healthcare, there appears to be an upward trend of public awareness over the issue. This past fall PBS's Frontline covered "Superbugs," drug-resistant bacteria, and their spread throughout hospitals and the difficulty of diagnosing infections early. Follow this link to watch the program. As these deadly bacteria show up in more hospitals, it will be vital to have a fast, easy and cost-effective way to detect the onset of infections. 
Isomark was also featured on the front page of the business section in the Wisconsin State Journal. The article provides a good overview on our company and current status, follow this link to read more.
In this newsletter we introduce the name for our device, discuss our upcoming human study and provide links to some papers recently published by our team. 


Joe Kremer, CEO

A few times each year we will update you on our progress. In between newsletters, please visit our website, www.isomark.com, for the most up-to-date information. If you would prefer not to receive Isomark updates, please click the "SafeUnsubscribe" link at the end of this email.



Finding the right name for a breakout product is never easy. It is vital to capture a new technology's attributes with an immediate, universal reference point. The Isomark Canary™ brings to mind the famous, carbon monoxide detectors used by miners. By "sniffing" a patient's breath, Isomark's Canary™ has a similar sentinel effect by alerting clinicians to a possible infection soon after onset. For more details on the technology, please see below for links to our recently published papers.



Following-up from Isomark's clinical study in 2012, a larger and more in-depth study will begin June 2014 at the University of Wisconsin Hospital and Clinics. This 110-patient study will focus on gathering additional comparative data to other infection detection methods with an emphasis placed on determining the time differential between Isomark's technology and standard practices. The information collected will also assist in determining cost-saving data and begin to identify how the Isomark Canary™ could alter the management of care scenario and improve patient outcomes. 
Isomark's breath-based infection detection technology is the result of years of research and development conducted by our scientific team. Recently the team had three papers published as featured articles in the Journal of Analytical Atomic Spectrometry (JAAS). These articles describe Isomark's underlying technology and the studies performed in order to demonstrate and further develop our technology. Here is the link to the JAAS's themed publication on "Novel stable isotopes in health sciences".
Following is a list and link to the individual articles:
Written by Daniel E. Butz (Isomark's CSO and Co-Founder), Shanon Casperson and Leah D. Whigham J. Anal. At. Spectrom., 2013, DOI: 10.1039/C3JA50327E.
Written by D. E. Butz (Isomark's CSO and Co-Founder), S. Morello, J. Sand, G. N. Holland (Isomark Strategic Advisor) and M. E. Cook (Isomark C0-Founder), J. Anal. At. Spectrom., 2013, DOI: 10.1039/C3JA50340B
Written by Juan P. Boriosi, Dennis G. Maki, Rhonda A. Yngsdal-Krenzc, Ellen R. Walda, Warren P. Porter (Isomark Co-Founder), Mark E. Cook (Isomark Co-Founder), and Daniel E. Bütz (Isomark's CSO and Co-Founder) J. Anal. At. Spectrom., 2013, DOI: 10.1039/C3JA50331C.

Isomark's patented non-invasive breath technology may allow for the early detection of infection.


Isomark's technology is under development and not available for use.


     Follow us on Twitter